my conflicts of interest are€¦ · wilke n et al. mrm 1993 • qualitative (eyeballing) •...
TRANSCRIPT
MY CONFLICTS OF INTEREST ARE
Grant support, Siemens Medical Solutions
Consultant, GlaxoSmithKline
Advanced Angioplasty 2007
MRI in Ischemic Heart Disease
Stefan Neubauer, MD FRCP FACC Professor of Cardiovascular Medicine
Department of Cardiovascular Medicine University of Oxford
John Radcliffe Hospital Oxford UK
Imaging in Ischemic Heart Disease
• Chest X-ray
• Echocardiography
• Nuclear scintigraphy
• Catheterisation Resolution
Information Radiation
Invasiveness • Cardiac MRI
The Comprehensive Cardiac MR (CMR) Examination
• Cardiac and great vessel anatomy
• Cardiac volumes and mass
• Global and regional contractile function
• Regional myocardial tissue perfusion
• Regional myocardial tissue characteristics:
Viability, oedema, inflammation, fibrosis, metabolism
• Coronary artery lumen, wall anatomy, blood flow
Goal: <30 min acquisition, <10 min post-processing
1. What CMR has to offer 2. CMR research in PCI
Comprehensive CMR Study
• High resolution anatomy
• Global / regional function
• Regional perfusion
• Viability/Oedema/Fibrosis
• Coronary Angiography
Horizontal long axis Vertical long axis
Cardiac Function: True-FISP MRI
Jane Francis, MR technologist, University of Oxford Centre for Clinical MR Research
Short axis Stack of short axes
+10mm +20mm +30mm +40mm
+50mm +60mm +70mm +80mm +90mm
Base
Apex
Simpson’s Rule
HLA cine Pre-vs. post-surgery MRI
pre post Norm EDV (ml) 1423 167 77-195 EF (%) 3 54 56-78
Selvanayagam J et al, Circulation 2003
Tissue Phase Mapping Regional Tissue Contractility
3D Velocities: Radial, circumferential, longitudinal
Petersen S et al, Radiology 2005
Dobutamine-Stress MR: 4-Chamber
rest 20 µg
40 µg 30 µg
Nagel E et al, Circulation 1999
Influence of image quality
0102030405060708090
100
good / very good moderate
sensitivity (DSE)specificity (DSE)sensitivity (DSMR)specificity (DSMR)
E. Nagel, Z Kardiol 1999
• High resolution anatomy
• Global / regional function
• Regional perfusion - GdDTPA
• Viability/Oedema/Fibrosis
• Coronary Angiography
Comprehensive CMR Study
<10s
Perfusion
10-20 min
Infarct
[Gd]
time
“First pass” study: Time-intensity curves
Normal
Ischemia/Infarct
LV Blood pool
Myocardial Perfusion - Quantification
Wilke N et al. MRM 1993
• Qualitative (eyeballing)
• Semi-quantification (upslope)
→ perfusion reserve
• Absolute quantification (ml/min x g)
Rest and stress perfusion (i.v. Adenosine 140µg/kg x min)
Regional Myocardial Perfusion
• n=84
• Prevalence of CAD 51%
• Sensitivity 88%
• Specificity 90%
• Diagnostic accuracy 89%
Nagel E el al. Circulation 2003
Wolff SD et al, Circulation 2004 Giang TH et al, Eur Heart J 2004
MR IMPACT II (Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial) A phase III multicenter, multivendor trial comparing perfusion cardiac magnetic resonance versus single photon emission computed tomography for the detection of coronary artery disease. J. Schwitter, 1 C. Wacker, 2 N. Wilke, 3
N. Al-Saadi, 4 N. Hoebel, 5 T. Simor 6
1 Zurich, Switzerland, 2 Würzburg, Germany, 3 Gainesville/Jacksonville, US 4 Berlin Germany, 5 Munich, Germany, GEHC, 6 Pecs, Hungary
• 33 centres, 1.5 Tesla, 465 patients • Patients with chest pain undergoing coronary angiography • CAD defined as >50% diameter stenosis in at least one vessel with at
least 2mm diameter
CardioVascular MR Center Zurich
0
0.25
0.5
0.75
1
0 0.25 0.5 0.75 1 1-Specificity
MR-IMPACT II 33 Centers – Multivendor: Dose 0.075 mmol/kg Gd-DTPA-BMA
*
Sens
itivi
ty
CardioVascular MR Center Zurich
SPECT all n=465 AUC: 0.65±0.03 P=0.0004
Perfusion-CMR n=465 AUC: 0.75±0.02
gated-SPECT n=277 AUC: 0.69±0.03 P=0.018 ungated-SPECT n=188 AUC: 0.63±0.04 P=0.023 P=ns vs Gated
0
0.25
0.5
0.75
1
0 0.25 0.5 0.75 1 1-Specificity
MR-IMPACT II - MVD 33 Centers – Multivendor: Dose 0.075 mmol/kg Gd-DTPA-BMA
Sens
itivi
ty
CardioVascular MR Center Zurich
SPECT all n=339 AUC: 0.72±0.03 P=0.003
Perfusion-CMR n=339 AUC: 0.80±0.03
gated-SPECT n=188 AUC: 0.75±0.04 P=0.040 ungated-SPECT n=140 AUC: 0.69±0.05 P=0.049 P=ns vs Gated 1-3 VD SPECT
MR-IMPACT II It is the largest multicenter MR/SPECT trial performed so far using 99mTc-tracers and ECG-gating (33 centers, 465 patients) It shows:
§ Perfusion-CMR (at 0.075 mmol/kg Gd-DTPA- BMA) is superior to SPECT for the detection of coronary artery disease
§ Perfusion-CMR is a short and safe test, is sensitive and specific, and can be recommended as an alternative for SPECT imaging in experienced centers
CardioVascular MR Center Zurich
Comparison of 3T vs. 1.5T CMR Perfusion 3T Stress 1.5T Stress
• 61 patients (age 64±8 years)
• Referred for diagnostic CA for investigation of exertional CP
• Stress/rest perfusion CMR at both 1.5T (Sonata) and 3T (Trio) on same day
1.00.80.60.40.20
1 - Specificity
1.0
0.8
0.6
0.4
0.2
0
Sens
itivi
ty
3 T AUC: 0.89±0.05
1.5 T AUC: 0.70±0.08
p < 0.05
1.00.80.60.40.20
1 - Specificity
1.0
0.8
0.6
0.4
0.2
0
Sens
itivi
ty
3 T AUC: 0.89±0.05
1.5 T AUC: 0.70±0.08
p < 0.05
1.00.80.60.40.20
1 - Specificity
1.0
0.8
0.6
0.4
0.2
0
Sens
itivi
ty
3 T AUC: 0.95±0.03
1.5 T AUC: 0.82±0.06
p < 0.05
1.00.80.60.40.20
1 - Specificity
1.0
0.8
0.6
0.4
0.2
0
Sens
itivi
ty
3 T AUC: 0.95±0.03
1.5 T AUC: 0.82±0.06
p < 0.05
MVD SVD
3T provided a significant increase in SNR (17±6 vs. 11±2; p<0.01) compared to 1.5T
Cheng A et al, JACC in press
• High resolution anatomy
• Global / regional function
• Regional perfusion
• Viability/Oedema/Fibrosis
• Coronary Angiography
Comprehensive CMR Study
Delayed Enhancement MRI
• 10 – 20 min post Gd DTPA
• Inversion recovery FLASH or True-FISP
• “Bright is dead”
• Normal, stunned, hibernating
myocardium is dark
Kim R et al, Circulation 1999
Kim R et al, NEJM 2001
Delayed Enhancement MRI In vivo infarct imaging
LV Function: cine MRI Myocardial Viability: DE-MRI
Superior to SPECT for the detection of sub-endocardial infarction Wagner et al Lancet 361:378
Example: Acute Antero-Septal Infarction
Relationship between transmural extent of HE before bypass surgery and likelihood of increased contractility after surgery
Transmural Extent of Hyperenhancement (%)
Impr
oved
con
trac
tility
(%)
0
20
40
60
80
100
All Dysfunctional Segments
Selvanayagam J et al Circulation 2004
Example: Viable vs. non-viable myocardium
Baseline Cine
Del. Enhancement
6 Months Cine
Delayed Enhancement Phenomenon
Acute Myocarditis
HCM: Fibrosis
Not specific for ischemic injury
M. Friedrich et al S. Petersen et al McCrohon et al Circulation 2003
DCM: Fibrosis
Imaging of Myocardial Oedema
Aletras et al Circulation 2006
Salvaged myocardium = Area at risk (T2w)– Area of necrosis (DE)
90 min occlusion reperfusion Microspheres: AAR TTC staining: AON
• High resolution anatomy
• Global / regional function
• Regional perfusion
• Viability/Oedema/Fibrosis
• Coronary Angiography
Comprehensive CMR Study
MR Coronary Angiography: Fundamental challenges
• Small structures (1-4mm diameter)
• Need 3 D resolution
• Move rapidly with cardiac cycle
and respiration (RCA by ~ 10cm)
Spatial resolution Temporal resolution
Cardiac cath 0.3 x 0.3 mm 8 ms (shutter speed)
CT Coronary Angiography
Spatial resolution Temporal resolution 0.4 x 0.4 x 0.4 mm 120 ms
Achenbach S, Erlangen University
MR Coronary Angiography
Spatial resolution Temporal resolution 0.6 x 0.6 x 0.6 mm minutes (navigator)
Sakuma H, Matsusaka Central Hospital, Mie, Japan
Future of Coronary MRA
• “Luminography”
• Vessel wall: Qualitative/quantitative analysis of atherosclerotic plaque
• Vessel function: Flow, flow velocity, distensibility
A vascular “one-stop-shop”
Wiesmann F et al Circulation 2003
0 200 400 600 800 1000
250
300
350
400
450
500
550
cros
s se
ctio
nal a
rea
(mm
2 )
time within cardiac cycle (ms)
area AA area PDA area DDA
Distensibility = (Amax – Amin)/Amin * (Pmax – Pmin)
CMR research in patients undergoing PCI
● CMR: New level of understanding of the
interrelations amongst coronary stenosis, myocardial blood flow, function and irreversible injury
1. Use of CMR in monitoring injury from revascularisation procedures
2. Blood flow in hibernating myocardium
With A. Banning, K. Channon, J. Selvanayagam
Use of CMR in monitoring injury from revascularisation procedures
Questions
● Occurrence and location of peri-procedural myocardial necrosis
in complex PCI?
● Relationship between magnitude of troponin rise to the volume
of myocardial tissue loss?
● Mechanisms of irreversible myocardial tissue injury?
New HE-8.5g; Trop I 4.8
48 consecutive patients undergoing complex PCI all received aspirin, clopidogrel and abciximab
24hr Pre and 24 hr Post PCI MRI; pre and 24 hr troponin I
Selvanayagam JB et al, Circulation 2005
● 2-vessel PCI ● Stent length >30mm
● Treated segment involved at least one side branch >20mm
● Chronic total occlusion
Complex PCI
Irreversible myocardial injury
New Hyperenhancement • 14/48 (29%) patients
4
8
n = 14 n = 48
5% of LV Mass
1.7 % of LV Mass
New
Hyp
eren
hanc
emen
t (gr
ams)
Selvanayagam JB et al Circulation 2005
Correlation of cTnI rise with new myocardial hyperenhancement
3
8
13
18 N
ew H
yper
enha
ncem
ent (
gram
s)
2 5 8 Troponin rise at 24 hrs (ųg/L)
r= 0.84
p<0.001
0
n = 48
Selvanayagam JB et al, Circulation 2005
Relationship Between Plaque Volume and Occurrence and Location of Peri-Procedural Myocardial Necrosis Following PCI
New HE • 15/64 (23%) vessels
2
4
n = 8 n = 7 New
Hyp
eren
hanc
emen
t (gr
ams)
p = 0.6
Distal Adjacent
Porto I et al, Circulation 2006
Example: Pre PCI
Angiogram IVUS DE-CMR
Porto I et al, Circulation 2006
Example: Post PCI
Angiogram IVUS DE-CMR
Porto I et al, Circulation 2006
Plaque Volume vs. Location of Peri-Procedural Myocardial Necrosis
} * } * } * } *
*p<0.001
No HE Distal Adjacent No HE Distal Adjacent
Porto I et al, Circulation 2006
Blood flow in hibernating myocardium
● Impairment in perfusion reserve is well recognized in myocardium supplied by significantly diseased coronary arteries (CAD)
● However, it is unknown whether resting blood flow is abnormal in such myocardium
● Studies to date mainly using PET have produced conflicting results
Background
Methods 27 patients undergoing percutaneous coronary intervention (PCI) ● one/ two vessel CAD (>85% stenosis by QCA) ● at least one dysfunctional segment
Cine & Rest
Perfusion DE CMR
PCI Cine
Rest Perfusion
DE CMR
Cine CMR
9 months 24h 24h
CMR Perfusion: Absolute quantification of blood flow
95% stenosis of proximal LAD
Selvanayagam JB et al, Circulation 2005
Blood flow in hibernating segments
• No delayed enhancement
• Significant recovery of function at 9 months
Selvanayagam JB et al, Circulation 2005
Segments with
Mean corrected
MBF pre-PCI
* **
* **
p < 0.001 p < 0.0001
NS
Selvanayagam JB et al Circulation 2005
Relationship between transmural scar and baseline/post- PCI blood flow
• Troponin elevation 24 hr post PCI represents new
myocardial injury • Both impairment of side branches and distal embolisation of
plaque material contribute to myocardial necrosis during PCI
• Resting myocardial blood flow is reduced in hibernating myocardium
Summary of Oxford PCI research studies
Clinical CMR Techniques on the Horizon • Regional strain (tissue phase mapping)
• Non-contrast perfusion (ASL)
• Oxygenation (BOLD)
• 23Na-Imaging
• Metabolism (MRS)
• 7 Tesla
• Molecular Imaging
Selvanayagam J et al, works in progress
Robson M et al Works in Progress
PCr
γ- !α- !β-ATP
2,3-DPG
PDE
! 5 !0 !-5 !-10 !-15 !-20 ppm
Non-invasive imaging tool
MRI in Ischemic Heart Disease
Multi-parametric phenotyping
Clinical studies of patients with IHD
Diagnostic Cardiology
Acknowledgments
OCMR Joseph Selvanayagam, Ranjit Arnold, Adrian Cheng
Collaborators Adrian Banning Keith Channon Michael Jerosch-Herold Italo Porto William van Gaal
Funding British Heart Foundation Medical Research Council The Wellcome Trust Siemens Medical Solutions
Myocardial Viability: Clinical Relevance
Schelbert H et al, Seminars in Nuclear Medicine 2002
Pagano et al, J Thorac Cardiovasc Surgery 1998
Cardiac Function: MR vs. Echo
• ~10 x higher contrast
• ~10 x more accurate
• True 3D
• Independent of geometric assumptions
• Any plane
• Right ventricular planes (ARVC)
• Independent of acoustic window
• Unlimited field of view
• Part of one-stop-shop
• Availability
• Cost
• 5% claustrophobic
• MR contraindications:
- Pacemaker
- Ocular foreign bodies etc.
+ -
Myocardial Perfusion: MR vs. Nuclear
• Much higher spatial resolution
• Transmural extent
• Radiation free
• Fast (15 minutes)
• Part of one-stop-shop
• Prognostic data missing!
• Quantification
• Data processing
+ ?
Myocardial ViabilityThe Clinical Problem:
Akinetic myocardium,supplied by stenosed coronary artery
Viable= Stunning, Hibernation
Non-viable= Scar
Revascularisation(PTCA, CABG)
No Revascularisation
Myocardial Viability: MRI > Echo or Nuclear
• Specific contrast for non-viable tissue
• Highest resolution (2 g detectable), quantification in g
• Transmural aspect of viability
• Radiation-free
• No need to stress the heart
• One contrast agent bolus for both perfusion and viability
• Part of one-stop-shop
Quantification of Global Myocardial Function
COMass EF EDV ESVl/ming % ml ml
LV 6.6±1.4112±27 69±6 150±31 47±15
RV ---38±8 61±6 173±39 69±22
Hudsmith et al, JCMR 2005 n = 108
Comparative Sample Sizes, Echo vs CMR
Change Echo CMR
LV EDV 8.3 mL 250 46 (18%)
LV ESV 5.5 mL 250 34 (14%)
LV EF 2.3% 250 50 (20%)
LV Mass 12.7 g 250 8 (3%)
Power 80%, P<0.05
Otterstad, Froeland, St John Sutton, Holme. Eur Heart J 1997
Bellenger, Davies, Francis, Marcus, Pennell. JCMR 2000
DSE DSMR p sensitivity 74.3% 88.7% < 0.05
specificity 69.8% 85.7% < 0.05
+ prediction value 81.0% 91.3% < 0.05
- prediction value 61.1% 78.3% < 0.05 accuracy 72.7% 86.0% < 0.005
E. Nagel, Circulation 1999;99:763-770
Methods ● The diagnostic coronary angiogram was used to define affected
myocardial segments
● Wall motion was assessed visually:
normal 1; hypokinetic 2; akinetic 3; dyskinetic 4.
● In each slice, MBF was determined for 8 myocardial sectors in ml/min/g by deconvolution of signal intensity curves with an arterial input function measured in the LV blood pool
Jerosch-Herold, M. et. al JMRI 2004
Results Coronary lesion severity was 80-95% stenosis by quantitative coronary angiography
Mean MBF normalized by rate pressure product (‘corrected MBF’) was 1.2+/-0.3 in segments without significant coronary stenosis and 0.7 +/-0.2 in segments with coronary stenosis pre PCI (z=23.9, p<0.001)
Early post procedure, the MBF was 1.2+/-0.2 in revascularised segments, and 1.3+/-0.2 in non-diseased segments
Methods
Prep
3 Min Adeno
0.14mg/ /kg/min
LE Imaging
BH BH
25‘
MR Study and Monitoring:
CardioVascular MR Center Zurich
–2 to 0h Vit Signs
12-ECG
1-1.5 h Vit S
12-ECG
24 h Vit S Phys
12-ECG Lab AE
1 h Vit S
12-ECG
- 36h to 0 h History
Phys. Exam Symptoms Preg Test Blood Lab
≤4 weeks: QCA
≤4 weeks: SPECT
≤4 weeks: QCA
≤4 weeks: SPECT
0.075 mmol/kg Gd-DTPA-BMA
0.075 mmol/kg Gd-DTPA-BMA
Vital signs (HR, BP, O2 sat, etc)
~1.5h
72 h AE 10‘
SPECT stress perfusion 99mTc: Sestamibi, Teboroxime, Tetrofosmin
SPECT Study: gated-SPECT (ungated-SPECT allowed if clinical routine)
Multi-Vendor 1-Day Protocol permitted
Preparation
Adeno 0.14mg/ /kg/min
Stress Rest
CardioVascular MR Center Zurich
Methods
Identical to stress perfusion 99mTc: Sestamibi, Teboroxime, Tetrofosmin
• Physics complex
• Nuclear spin
• External magnetic field
• RF waves -> FID
MR (NMR) - Nuclear Magnetic Resonance
• Magnetic field gradient
• MR image contrast: - Spin density - Relaxation (T1, T2) - Flow - Pulse sequence
Nature 1973; 242:190-191